A HCP called to inquire about the safety of administering a second dose of VARIVAX to a 55 year old patient who received the first dose of VARIVAX on 06/29/2023 due to having a negative varicella titer.  The patient broke out in a rash on or around J; A HCP called to inquire about the safety of administering a second dose of VARIVAX to a 55 year old patient who received the first dose of VARIVAX on 06/29/2023 due to having a negative varicella titer.  The patient broke out in a rash on or around J; crusted lesions; minor itching; This spontaneous report was received from a physician and refers to a 55-year-old female patient.  The patient's medical history included drug intolerance for sertraline and atorvastatin, sleep apnoea, obesity, and liver fatty. The patient's concurrent conditions included type 2 diabetes mellitus, hypertension, hyperlipidemia. Historical drugs included sertraline and atorvastatin. Concomitant medications included metformin, benazepril, empagliflozin (JARDIANCE), esomeprazole magnesium (NEXUM), rosuvastatin, dulaglutide (TRULICITY), estradiol, fesoterodine, colecalciferol (VITAMINE D), lactobacillus reuteri (PROBIOTICA) and fish oil.   On 29-JUN-2023, due to having a negative varicella titer, the patient received the first dose of varicella virus vaccine live (oka/merck) (VARIVAX) injection, 0.5 milliliter, lot #W025274, has been verified to be a valid lot number, expiration date was 10-AUG-2024, administered for prophylaxis in left arm (strength, and route of administration were not provided) and sterile diluent solution for injection/infusion, injection with varicella virus vaccine live (oka/merck) (VARIVAX) (batch # W032818, not valid, expiry date was reported as 01-MAY-2025, strength, route of administration, and indication were not provided). On an unknown date, the patient received two other vaccines of hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, 1 milliliter, lot #W023489, has been verified to be a valid lot number, expiration date was 27-DEC-2023, administered for prophylaxis in right arm (strength, and route of administration were not provided); the patient also received diphtheria vaccine toxoid, pertussis vaccine acellular 3-component, tetanus vaccine toxoid (BOOSTRIX), 0.5ml via injection in the left arm, batch #M4E4A, not valid, expiration date reported as 05-OCT-2025, administered for prophylaxis (strength, formulation, and route of administration were not provided). The location and contact information the clinic and who administered the vaccines were unknown by the reporter.  The patient broke out in a rash on around 10-JUL-2023 with approximately 50 papules. The patient was seen in the office on 20-JUL-2023. By the time the patient was evaluated the patient only had one crusted lesions (scab), the rest were papules, and no vesicles were present. No treatment was provided because the patient only had minor itching (pruritus) and was otherwise asymptomatic and improving with no new lesions. At the reporting time, the patient was recovering from the events of rash, papule, scab and pruritus. The action taken was not applicable.   The casualty between all the events and suspect vaccines was not provided.